News & Publications

TekCyte, has over the years developed collaborations with multiple companies to enhance product performance and deliver added value to their products. Our commitment to continuous improvement through specialised testing and advanced coating techniques enables our partners in the medical industry to bring truly innovative solutions to market. This case study highlights our successful partnership with […]

Bringing new medical devices to patients is often challenging, especially when they involve complex drug delivery. Companies often struggle to turn their ideas into working devices and produce them consistently in large numbers while keeping quality high and patients safe. This case study shows how TekCyte helps solve these common industry problems. Our partnership with […]

TekCyte enters the second quarter of 2025 with accelerating activity across our technology portfolio, commercial partnerships and contract services. The year ahead will be shaped by global collaborations, clinical translation milestones, and the continued development of BIOINVISIBLE™ – our market-leading low-fouling, anti-infection coating technology. Our technologies are gaining recognition across medical, industrial and research sectors, […]

The increasing use of implantable medical devices has transformed healthcare outcomes across orthopaedics, dentistry, vascular and reconstructive procedures. From hip and knee replacements to vascular stents and hernia meshes, these devices restore function, improve quality of life and, in many cases extend the lives of patients. Yet a silent threat undermines their effectiveness – biofilm […]

In the field of biomedical technology, innovation and successful commercialisation are key indicators of a company’s potential. TekCyte Limited has demonstrated both, with its ground-breaking CYPATCH coating technology recently acquired by Cynata Therapeutics (ASX: CYP). This acquisition was driven by promising clinical trial results and highlights TekCyte’s capacity to develop and deliver impactful medical solutions. […]

Adelaide-based company TekCyte is now seeking investors to fund the expansion of their revolutionary medtech BIOINVISIBLE – a drug-free medical device coating that could curb global rates of infection from implanted devices and potentially save thousands of lives each year. Developed for commercialisation out of the Cell Therapy Manufacturing Cooperative Research Centre, based at the […]

TekCyte’s next-generation medical device coating technology is helping to create safer and better outcomes for patients. It is anti-thrombogenic, anti-proliferative and evidence also now demonstrates extreme reduction in biofilm. The BIOINVISIBLE™ globally patented coating technology is an ultra-thin, highly hydrophilic hyperbranched polyglycerol (HPG) polymer that can be chemically bonded to, for example, a stent or […]

The field of biomedical science and technology has been actively working on improving vascular stents to solve problems relating to the body’s reaction to their presence. Advances in nanotechnology are leading to improved vascular stent coating materials, in some cases making the implantable medical device seem invisible to the body. This is helping vascular surgeons […]

Advances in biomedical equipment, systems and materials are opening new opportunities to create custom made biomedical coatings for the medical industry that have previously been unavailable or too expensive to consider developing for commercial applications. Medical Device Product Development “Our combined biological and biomaterials expertise means we can design ultra-thin, scalable coatings tailored to specific […]

A non-pharmacological approach to reducing device-triggered thrombosis and restenosis Synthetic materials are commonly rejected from the body’s natural defence mechanism. However, there is untapped potential to develop synthetic materials with the innate ability to avoid the body’s natural defence mechanisms from activating. While current materials used in devices has an acceptable level of biocompatibility, there […]

By Dr Tony Simula, PhD MBA BSc(Hons), CEO at TekCyte Peripheral arterial disease (PAD) is characterized by reduced blood flow in the arteries of the lower extremities, due to atherosclerotic occlusive disease. With over 200 million people now affected by the disease worldwide, it is the third leading cause of atherosclerotic vascular morbidity following stroke […]

Every invention takes a team to bring it to market. It requires research and development, with a strong team carrying it through to the stage of commercialisation. The story behind BIOINVISIBLE™ is no different. With highly skilled researchers from a number of different scientific disciplines, a project team was created to work together to improve […]